Xenon Pharmaceuticals Inc. — Q2 2023 Form 10-Q
Business context and period. This clinical-stage biopharmaceutical company focuses on neurological disorders, particularly epilepsy. This unaudited report covers the quarter and six months ended June 30, 2023; amounts are in U.S. dollars unless stated otherwise. Xenon had no approved products and no product-sales revenue.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0.5 million | $0 | $9.3 million |
| Research and development expense | $44.0 million | $22.1 million | $83.6 million | $41.5 million |
| General and administrative expense | $11.6 million | $8.7 million | $21.1 million | $15.5 million |
| Net loss | $47.5 million | $31.2 million | $89.2 million | $50.8 million |
| Basic and diluted loss per share | $0.72 | $0.55 | $1.36 | $0.91 |
- At June 30, cash and cash equivalents were $64.6 million and marketable securities were $587.6 million, totaling $652.2 million. Total assets were $684.9 million; shareholders’ equity was $646.5 million.
- Six-month operating cash use was $67.6 million, versus $35.3 million in 2022. Investing activities provided $74.5 million, mainly reflecting net redemptions of marketable securities; financing activities provided no cash.
- Total liabilities were $38.4 million, including $11.5 million of operating lease liabilities. The filing reports no debt balance. Accumulated deficit was $571.9 million.
- No operating margin is meaningful to assess because revenue was nil in 2023.
Material changes versus prior period
- Six-month revenue fell by $9.3 million: the 2022 period included a Neurocrine collaboration milestone and research-service revenue; no revenue was recognized in 2023. The research collaboration ended in June 2022.
- Six-month R&D expense rose $42.1 million, chiefly from XEN1101 Phase 3 trial activity, the X-NOVA MDD study, increased headcount and stock-based compensation. G&A expense rose $5.6 million, primarily from personnel-related costs, with higher legal and market-research costs also noted.
- Higher investment yields and balances increased six-month interest income to $11.9 million from $1.2 million. Unrealized gains on trading securities were $2.9 million, compared with $4.7 million of losses in 2022.
- Common shares outstanding were 63.7 million at June 30, 2023, versus 62.6 million at December 31, 2022. At August 4, 2023, the company reported 64.1 million shares outstanding, plus pre-funded warrants, options and another warrant.
Outlook, management commentary and risks
- Management expected available cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures for at least the next 12 months, while cautioning that estimates could prove wrong and additional financing may be needed. The company expects continued losses and substantial expense growth.
- XEN1101 is in Phase 3 epilepsy trials X-TOLE2 and X-TOLE3 for focal onset seizures and X-ACKT for primary generalized tonic-clonic seizures. Enrollment was complete in the Phase 2 X-NOVA MDD study; topline results were anticipated in late November to mid-December 2023.
- Neurocrine had completed enrollment in a Phase 2 NBI-921352 adult focal-seizure trial, with data expected in Q4 2023; a pediatric SCN8A-DEE Phase 2 trial was also underway. Xenon’s potential collaboration milestones and royalties depend on future development and commercial outcomes.
- Xenon stated it would no longer pursue clinical development of XEN496. It had not sold shares under its $250 million at-the-market program as of June 30, 2023.
- Key risks include clinical-trial efficacy, safety, enrollment and timing; regulatory uncertainty; dependence on collaborators and third-party manufacturers; intellectual-property protection; cybersecurity; competition; and potential future capital needs or shareholder dilution. The company reported no legal proceeding expected by management to have a material adverse effect.
- Market risks include currency exposure, which the company does not currently hedge, and interest-rate sensitivity: a 100-basis-point unfavorable rate change was estimated to reduce marketable-securities fair value by approximately $3.0 million. Management said inflation had not materially affected results to date, but costs may rise.
Investor facts to verify
- Progress, enrollment and eventual results for the three XEN1101 Phase 3 epilepsy trials, and the timing and findings of X-NOVA.
- Neurocrine’s Q4 2023 NBI-921352 data and continued progress in the pediatric SCN8A-DEE study, including any milestones or royalties payable to Xenon.
- Whether the stated minimum 12-month liquidity runway remains adequate as trial spending increases, and whether Xenon uses its ATM or pursues other financing.
- Future cash burn, marketable-securities values and interest-rate exposure, as well as potential dilution from shares, options and remaining pre-funded warrants.